ClinicalTrials.gg
CompletedNCT07937722Updated Nov 16, 2026

The Effect of Mindfulness-Based Cognitive Therapy on Nausea and Vomiting Management and Quality of Life in Oncology Patients

An interventional study of Mindfulness Based Cognitive Therapy (MBCT) in Chemotherapy, Cancer and Chemotherapy Induced Nausea and Vomiting, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Feb 2023, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study evaluates the effect of Mindfulness-Based Cognitive Therapy (MBCT) on chemotherapy-induced nausea and vomiting management and quality of life in oncology patients. Patients undergoing chemotherapy were allocated to either an intervention group receiving MBCT or a control group receiving routine care. The primary objective is to investigate the efficacy of the MBCT intervention in reducing nausea and vomiting symptoms and improving overall quality of life.

02

Conditions studied

  • Chemotherapy
  • Cancer
  • Chemotherapy Induced Nausea and Vomiting

Keywords

  • quality of life
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 54 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Saglik Bilimleri Universitesi is the lead sponsor of 456 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Diagnosed with cancer and scheduled to receive highly emetogenic chemotherapy.

Able to read and write.

Older than 18 years.

Able to communicate without a language barrier.

Willing to participate and provide .

No diagnosed mental or psychiatric disorder, with a (MMSE) score of 24 or higher.

Access to a device suitable for attending online sessions, such as a smartphone, computer, or tablet.

About to start a new chemotherapy regimen.

No hearing or visual impairment.

Exclusion criteria

Exclusion Criteria:

  • Unable to comply with the planned interventions.

Hearing impairment.

Unwilling to participate.

Intellectual disability or difficulties with comprehension.

A (MMSE) score of 23 or lower.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    MBCT GROUP

    Patients participated in the Mindfullness based Cognitive Therapy Program alongside routine oncology care

    Behavioral: Mindfulness Based Cognitive Therapy (MBCT)

  • No intervention
    Control Group

    Patients received routine oncology nursing care without MBCT sessions.

Interventions

  • BehavioralMindfulness Based Cognitive Therapy (MBCT)

    8 week structured MBCT sessisons focusing on minfullness practices, cognitive reframing and symptom awareness.

06

What researchers measure

Primary outcomes

  1. Chemotherapy induced Nausea and Vomiting Score

    Assessed using the Rhodes Index of Nausea, Vomiting, and Retching (INVR). The scale consists of 8 items evaluating the duration, frequency, and distress of nausea, vomiting, and retching on a 5-point Likert scale (total score ranges from 0 to 32). Higher scores indicate greater frequency, duration, and distress caused by nausea and vomiting.

    Time frame: Baseline (week 1) and post-intervention (week 9)

Secondary outcomes

  1. Quality of Life Score

    Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, Turkish version). The tool evaluates global health status, functional scales, and symptom scales. Raw scores are linearly transformed into a 0 to 100 scale. Higher scores on the global health status and functional scales represent better quality of life and higher functioning, whereas higher scores on the symptom scales represent higher levels of symptomatology/problems.

    Time frame: Baseline (week 1) and post-intervention (week 9)

07

Study locations

1 site
  • Medical Oncology Department of Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jun 2023, 4 months.

Of 1,986 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 4 months is below that.

Counting every sponsor, half of 2,061 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Feb 1, 2023
Primary completionActual
Jun 10, 2023
CompletionActual
Jun 20, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937722
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Feb 1, 2023
Primary completion
Jun 10, 2023
Completion
Jun 20, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion